Bisc Therapeutics
1 known investors
Bisc Therapeutics develops Bax inhibitor therapies designed to prevent retinal cell death and preserve vision in patients with retinal degenerative diseases such as age-related macular degeneration, glaucoma, and inherited retinal disorders. The company operates in the biotech/ophthalmology therapeutics space.
BiotechHealthtech